Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences
01 sept. 2022 16h01 HE
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
aTyr Pharma to Present at March Investor Conferences
25 févr. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
09 sept. 2020 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
H.C. Wainwright reiterates ‘Buy’ for Co-Diagnostics (NASDAQ:CODX) with a $35 Price Target as COVID-19 Surge Boosts Testing Demand
14 juil. 2020 07h30 HE
|
BDA International
New York City, July 14, 2020 (GLOBE NEWSWIRE) -- Analyst Yi Chen of H.C. Wainwright & Co. reiterated his ‘buy’ coverage on Co-Diagnostics (NASDAQ:CODX), the Utah-based molecular diagnostics...
Co-Diagnostics (NASDAQ:CODX) Analysts Set Price Target Between $30 and $36
28 mai 2020 09h00 HE
|
BDA International
New York City, May 28, 2020 (GLOBE NEWSWIRE) -- Analysts from H.C. Wainwright, Maxim Group and Litchfield Hills have all upgraded or reiterated Co-Diagnostics (NASDAQ: CODX) as “Buy” rating in the...
Co-Diagnostics (NASDAQ:CODX) Reiterated Buy; Joins Distinguished Group Racing to Meet Unprecedented Global Demand for COVID-19 Testing
25 mars 2020 11h30 HE
|
BDA International
NEW YORK CITY, March 25, 2020 (GLOBE NEWSWIRE) -- The global shortage of COVID-19 testing kits is hitting the United States and other nations hard, but a recent FDA policy change means that...
Buy for Co-Diagnostics (NASDAQ:CODX) Reiterated by H.C. Wainwright with $20 Price Target
11 mars 2020 09h30 HE
|
BDA International
New York City, March 11, 2020 (GLOBE NEWSWIRE) -- Analyst Yi Chen released additional coverage on Co-Diagnostics (NASDAQ:CODX), a Utah-based molecular diagnostics company, raising the firm’s price...
H.C. Wainwright Reiterates Buy Rating for Co-Diagnostics (NASDAQ:CODX) Following News of Expansion into Africa
31 oct. 2019 07h00 HE
|
BDA International
New York, Oct. 31, 2019 (GLOBE NEWSWIRE) -- H.C. Wainwright has reiterated their “Buy” rating for Co-Diagnostics, Inc. (Nasdaq: CODX), a biotech with a patented platform for the development of...
INTERPACE DIAGNOSTICS ANNOUNCES PARTICIPATION AT THE 20TH ANNUAL GLOBAL INVESTMENT CONFERENCE SPONSORED BY H.C.WAINWRIGHT & CO.
27 août 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...